FibroBiologics Stock (NASDAQ:FBLG)

Ownership Financials Chart

Previous Close

$0.96

52W Range

$0.76 - $13.59

50D Avg

$1.13

200D Avg

$2.40

Market Cap

$41.13M

Avg Vol (3M)

$308.61K

Beta

0.18

Div Yield

-

FBLG Company Profile

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Feb 01, 2024

Website

FBLG Performance

FBLG Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-13.74M	$-8.89M	$-4.47M
Net Income	$-11.16M	$-16.48M	$-5.12M
EBITDA	$-13.74M	$-15.90M	$-4.37M
Basic EPS	$-0.34	$-0.59	$-0.16
Diluted EPS	$-0.34	$-0.68	$-0.16

Fiscal year ends in Dec 24 | Currency in USD